Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dual Prevention Pill
- Development stage
- Phase 2
- Lead developer
- Viatris
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The Dual Prevention Pill (DPP) is a novel, single, co-formulated daily oral medication designed to prevent both HIV infection and unintended pregnancy. It combines two established pharmaceutical components: oral pre-exposure prophylaxis (PrEP) and combined oral contraception (COC). The first-generation DPP, developed by Viatris, integrates Tenofovir Disoproxil Fumarate and Emtricitabine for HIV prevention, and Levonorgestrel and Ethinyl Estradiol for contraception. This multi-purpose prevention technology aims to address critical public health needs, particularly in regions with high rates of HIV incidence among women of reproductive age and unmet family planning needs. It is administered as a daily oral pill, typically following a 21-7 regimen where 21 tablets contain both antiretroviral and contraceptive agents, and 7 tablets contain only the antiretroviral agents to maintain HIV protection during the contraceptive-free interval.
- Brand names
- Dual Prevention Pill
- Other names
- pre-exposure prophylaxis + combined oral contraceptive
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseESR2 (ERβ)ESR1 (ERα)PR (Progesterone receptor)
Beyond the preview
Go deeper on Dual Prevention Pill.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dual Prevention Pill.